Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP4 deficiency enhances sensitivity to ATM inhibitor by impairing DNA damage repair in melanoma

30 Jan 2025

Abstract excerpt

Besides the important pathogenic mechanisms of melanoma, including BRAF-driven and immunosuppressive microenvironment, genomic instability and abnormal DNA double-strand breaks (DSB) repair are significant driving forces for its occurrence and development. This suggests investigating novel therapeutic strategies from the synthetic lethality perspective. Poly (ADP-ribose) polymerase 4 (PARP4) is known to be a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Integrated Circuits and Semiconductor Failure Analysis
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39885134
DOI: 10.1038/s41420-025-02296-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP4 deficiency enhances sensitivity to ATM inhibitor by impairing DNA damage repair in melanomaPMID 39885134Read ↗

PARP Inhibition as a Treatment Modality in Melanoma: What We Have Learned and What We Hope to AchieveSemantic proximity Read ↗

PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?Semantic proximity Read ↗

PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In VivoSemantic proximity Read ↗

PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomasSemantic proximity Read ↗

The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host InteractionsSemantic proximity Read ↗

Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma TreatmentSemantic proximity Read ↗

Advances and perspectives of PARP inhibitorsSemantic proximity Read ↗

Homologous Recombination Deficiency (HRD) in Cutaneous OncologySemantic proximity Read ↗

PARP1 as a Marker of an Aggressive Clinical Phenotype in Cutaneous Melanoma-A Clinical and an In Vitro Study.Semantic proximity Read ↗

Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer TherapeuticsSemantic proximity Read ↗

Therapeutic Targeting of Poly(ADP‐Ribose) Polymerase‐1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future OpportunitiesSemantic proximity Read ↗

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.